Search clinical trials for: Avelumab in combination

Total 456776 results

National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Metastatic Merkel Cell Carcinoma | Refractory Merkel Cell Carcinoma | Locally Advanced Merkel Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada, Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics

Recruiting

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Locally Advanced or Metastatic Urothelial Carcinoma

Korea, Republic of, United States, Taiwan, Australia, United Kingdom, France, Greece, Italy, Belgium, Spain, Canada, Denmark, Germany
University of Campania "Luigi Vanvitelli"

Recruiting

CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Metastatic Colorectal Cancer

Italy
Hospital of Macerata

Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)

Italy
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Central Nervous System Tumors

Korea, Republic of, United States, Canada, Germany, France
M.D. Anderson Cancer Center

Recruiting

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 and other conditions

United States
Ulrik Lassen
GlaxoSmithKline; Pfizer; Roche Pharma AG

Recruiting

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget)

Neoplasms | Cancer | Tumors | Neoplasia

Denmark
Maria Sklodowska-Curie National Research Institute...

Recruiting

A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)

Gastrointestinal Stromal Tumors

Poland
National Cancer Institute (NCI)

Recruiting

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Cholangiocarcinoma | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v8 | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma...

United States
Gachon University Gil Medical Center
Merck KGaA, Darmstadt, Germany; Chong Kun Dang Pharmaceutical Corp.

Recruiting

Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment (EAGLES)

Leiomyosarcoma Metastatic

Korea, Republic of
AIO-Studien-gGmbH
Pfizer; Crolll Gmbh

Recruiting

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy (PREPARE)

Renal Cell Carcinoma, Metastatic | Renal Cell Cancer, Recurrent

Germany
Versailles Hospital

Recruiting

Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW)

Leukemia, Myeloid, Chronic-Phase

France
University College, London
Merck KGaA, Darmstadt, Germany

Active, not recruiting

EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)

Head and Neck Cancer | Squamous Cell Carcinoma

United Kingdom
4SC AG

Completed

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)

Merkel Cell Carcinoma

Spain, Netherlands, Belgium, Germany, France, Italy
Memorial Sloan Kettering Cancer Center
ENABLE MEDICINE

Active, not recruiting

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Sarcoma | Leiomyosarcoma | High Grade Sarcoma | Undifferentiated Pleomorphic Sarcoma | Advanced Sarcoma | Myxofibrosarcoma | Dedifferentiated Liposarcoma

United States
Georgetown University
Pfizer

Active, not recruiting

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Breast Cancer

United States
Pfizer

Terminated

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Non-Small Cell Lung Cancer | Urothelial Cancer

Korea, Republic of, United States, Taiwan, Poland, Spain, Russian Federation, Italy, Hungary
Gilead Sciences
Merck KGaA, Darmstadt, Germany

Completed

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Ovarian Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany

Active, not recruiting

An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)

Carcinoma, Renal Cell

Germany, Greece, Belgium, Russian Federation
Johannes Gutenberg University Mainz
Ipsen; Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA...

Active, not recruiting

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Cancer

Germany
Exelixis

Active, not recruiting

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)

Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
University of Oklahoma
EMD Serono; Aravive, Inc.

Active, not recruiting

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (COAXIN)

Urothelial Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
Pfizer

Completed

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Advanced Renal Cell Carcinoma

United Kingdom
Leap Therapeutics, Inc.
Pfizer; Merck KGaA, Darmstadt, Germany

Terminated

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Solid Tumors | Advanced Triple Negative Breast Cancer | Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer | Advanced Metastatic Castration-Resistant Prostate Cancer | Advanced Platinum-Resistant Ovarian Cancer

United States
Oncolytics Biotech
PrECOG, LLC.

Active, not recruiting

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Breast Cancer Metastatic

United States
Promontory Therapeutics Inc.
Pfizer; EMD Serono

Completed

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1)

Non-Small Cell Lung Cancer (NSCLC)

United States, Switzerland
Genome & Company
Merck KGaA, Darmstadt, Germany

Active, not recruiting

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Pfizer

Terminated

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

United States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
Fate Therapeutics

Terminated

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Fate Therapeutics

Terminated

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | GastroEsophageal Cancer

United States
Pfizer

Terminated

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Non-small Cell Lung Cancer | Urothelial Cancer

Spain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair Deficiency

United States
Genome & Company
Pfizer; Merck KGaA, Darmstadt, Germany

Completed

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Urothelial Carcinoma

United States
Pfizer

Completed

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

Ovarian Cancer

United States, Canada, Australia, France, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Austria, Denmark, Hungary, Singapore, Hong Kong, Belgium, Japan, Ireland, Italy, Netherlands, Czechia, Poland, Switzerland, Russian... and more
Pfizer

Terminated

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Non-Small Cell Lung Cancer

United States, Australia, Japan, Korea, Republic of, Spain
Pfizer

Terminated

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Advanced Cancer

United States, Canada, United Kingdom, Taiwan, Australia, France, Japan, Poland
Hellenic Cooperative Oncology Group
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer (PAVE)

Small Cell Lung Carcinoma

Greece
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Stage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Urethral Urothelial Carcinoma | Stage II Bladder Cancer AJCC v8 | Stage II Renal Pelvis... and other conditions

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab-M3814 Combinations

Solid Tumors | Oncology

United States
Vaximm GmbH
Pfizer; Merck KGaA, Darmstadt, Germany

Active, not recruiting

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Recurrent Glioblastoma

Germany
Yousef Zakharia
Pfizer; University of Iowa

Active, not recruiting

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

Urothelial Carcinoma

United States
AIO-Studien-gGmbH

Completed

Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (AVETUX)

Metastatic Colorectal Cancer

Germany
National Cancer Institute (NCI)

Completed

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

Mycosis Fungoides | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Peripheral T-cell Lymphoma NOS

United States
Debiopharm International SA

Completed

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Neoplasms | Carcinoma, Non-Small-Cell Lung

Canada, Poland, Romania
Vaccinex Inc.
Merck KGaA, Darmstadt, Germany

Completed

VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer (CLASSICAL-Lung)

Carcinoma, Non-Small-Cell Lung

United States
Vyriad, Inc.

Completed

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Malignant Solid Tumour

United States
ImmunityBio, Inc.

Withdrawn

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States

Search clinical trials for: Avelumab in combination

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations